Zai Lab Limited ZLAB
24.60 USD -1.44 (-5.53%)
At closeNov 13, 2026, 4:00 PM EST
24.60 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
23.50 Day range 25.94
16.30 52-week range 27.00
- YTD
- +39.46%
- 1 year
- +13.21%
News
businesswire.com Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in…
businesswire.com Zai Lab Announces Participation in Investor Conferences in November 2026 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following…
benzinga.com Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for…
benzinga.com Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing Zai Lab reports positive Phase 1 data for ZL-1503, showing 90% biomarker inhibition through Week 12 and strong safety in healthy volunteers.
seekingalpha.com Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
businesswire.com Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results…
zacks.com Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High? The consensus price target hints at a 40.2% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
benzinga.com Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium In the Phase 1b/2 trial, zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, demonstrated clinically meaningful responses in patients with previously treated advanced…
benzinga.com Zai Lab Q3 2026 Earnings Call Transcript Zai Lab (NASDAQ:ZLAB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Zai Lab Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $108.208M Beat $105.825M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 33.33 percent decrease over losses of $(0.03) per…
benzinga.com Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3 At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of…